Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PRISM BioLab Co. LTD ( (JP:206A) ) has shared an update.
PRISM BioLab reported non-consolidated revenue of ¥253 million for the six months to March 31, 2026, a 15.8% year-on-year increase, but the company remained loss-making with a net loss of ¥603 million and basic loss per share of ¥16.34. Total assets declined to ¥2.59 billion and the equity ratio fell to 81.8%, while the company maintained a zero-dividend policy for the period and withheld a full-year earnings forecast, citing the inability to make a reasonable estimate.
Equity decreased from ¥2.71 billion at the previous fiscal year-end to ¥2.13 billion, reflecting ongoing operating losses despite modest revenue growth. Management’s decision not to issue guidance and to continue suspending dividends underscores the company’s early-stage, high-risk profile, with implications for shareholders who must weigh capital erosion against the potential long-term upside of its biotech pipeline.
More about PRISM BioLab Co. LTD
PRISM BioLab Co. Ltd. is a Japan-based biotechnology company listed on the Tokyo Stock Exchange. Operating under Japanese GAAP, it focuses on drug discovery and related bio-science activities, positioning itself in the emerging life sciences segment of the Japanese equity market.
Average Trading Volume: 738,850
Technical Sentiment Signal: Sell
Current Market Cap: Yen6.39B
Find detailed analytics on 206A stock on TipRanks’ Stock Analysis page.